Abstracts - faqs.org

Abstracts

Biological sciences

Search abstracts:
Abstracts » Biological sciences

Yan functions as a general inhibitor of differentiation and is negatively regulated by activation of the Ras1/MAPK pathway

Article Abstract:

Proper cell differentiation in the neuronal and nonneuronal tissues during development in Drosophila is affected by the stability of yan because it is involved in the ability of the cell to respond to inductive signals during development. Phosphorylation of the yan gene by the mitogen-activated protein kinase affects the subcellular position of yan and causes it to degrade. The yan gene inhibits cell differentiation and is an antagonist to the proneural signal which is mediated by the Ras1/MAPK pathway. Neural development is inhibited in mutants deficient in the MAPK phosphorylation site.

Author: Rubin, Gerald M., Rebay, Ilaria
Publisher: Elsevier B.V.
Publication Name: Cell
Subject: Biological sciences
ISSN: 0092-8674
Year: 1995
Cell differentiation, Phosphorylation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism

Article Abstract:

Researchers have analyzed the functional relationship between the Seven In Absentia (SINA), Phyllopod (PHYL) and Tramtrack (TTK88) proteins. Particular attention was given to the regulation of TTK88 during Drosophila eye development. It was possible to establish that induction of PHYL expression prompts down-regulation of TTK88 by a process which needs SINA. TTK88 was found to be a repressor of photoreceptor cell fate determination. PHYL links with SINA to target TTK88 for degradation, thus forming a permissive environment for photoreceptor differentiation.

Author: Rubin, Gerald M., Kwan, Elaine, Neufeld, Thomas P., Tang, Amy H.
Publisher: Elsevier B.V.
Publication Name: Cell
Subject: Biological sciences
ISSN: 0092-8674
Year: 1997
Metabolic regulation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Kuzbanian controls proteolytic processing of notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis

Article Abstract:

Lateral inhibition process during Drosophila neurogenesis requires Notch and the disintegrin metalloprotease encoded by the kuzbanian (KUZ) gene. A mutant KUZ protein which lacks protease activity functions as a dominant-negative form in Drosophila. The overproduction of primary neurons resulting from lateral inhibition of Xenopus indicates an evolutionary role for KUZ. Furthermore, Notch was found to be an in vivo substrate for the KUZ protease.

Author: Rubin, Gerald M., Pan, Duojia
Publisher: Elsevier B.V.
Publication Name: Cell
Subject: Biological sciences
ISSN: 0092-8674
Year: 1997
Proteins, Developmental neurology, Proteolysis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Physiological aspects, Drosophila
Similar abstracts:
  • Abstracts: Influence of carbohydrate starvation and arginine on culturability and amino acid utilization of Lactococcus lactis subsp. lactis
  • Abstracts: Carbapenem antibiotic production in Erwinia carotovora is regulated by CarR, a homologue of the LuxR transcriptional activator
  • Abstracts: Characterization and environmental regulation of outer membrane proteins in Xenorhabdus nematophilus. Purification and characterization of Xenorhabdicin, a phage tail-like bacteriocin, from the lysogenic strain F1 of Xenorhabdus nematophilus
  • Abstracts: Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster
  • Abstracts: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.